RxDoctor Payments Data

Cheong Lee, MD

Vascular Surgery · Skokie, ILNPI 1699851915

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (56.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Medtronic at 60.0% of the total. Reporting peaked in 2024 at $10,510 and has fallen 82.9% since, to $1,799 in 2025.

$19,394in general payments, 2019–2025

Across 150 payments — averaging $129.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$12K
  • W. L. Gore & Associates, Inc.$3K
  • Cook Incorporated$1K
  • Cook Medical LLC$835
  • Endologix LLC$468
  • BD$399
  • plus $2K from 16 others
$9,277in research payments, 2019–2025

Across 4 payments — averaging $2319.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endologix LLC$9K

What the payments were for

  • Consulting fees$9005%
  • Travel & lodging$10,98457%
  • Food & beverage$7,51039%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,394 in reported general payments places this provider in the 80th percentile of 170 vascular surgery providers in Illinois.

See all vascular surgery providers in Illinois

Medicare billing

Part B allowed, 2024
$281,146
Medicare patients
1,477
Services billed
2,321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban23$23,367
EliquisApixaban16$18,785
ClopidogrelClopidogrel Bisulfate73$781
Cilostazol29$528
Gabapentin26$322
Atorvastatin Calcium23$206
Celecoxib22$201
Rosuvastatin Calcium13$167
Baclofen11$74
Meloxicam22$70

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$150$23,36723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 170 vascular surgery providers in Illinois.

Other vascular surgery in Skokie

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →